However, in our in vitro TEM study, we found consistently that TFPI enhanced CXCL12-mediated cell migration through binding to GPC3, activating β-catenin, and finally upregulating CXCR7 expression in the CLL cells. The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.